Thomas Schinecker, Roche CEO (ddp images/Sipa USA/Sipa via AP Images)
July 25, 2024 07:16 AM EDTUpdated 07:31 AM
R&D
Pharma

Roche cuts two more TIG­IT tri­als, plans ac­cel­er­at­ed time­line for obe­si­ty drugs

Amber Tong

A year in­to Roche’s com­pre­hen­sive port­fo­lio re­view, the Swiss phar­ma said it has now tak­en out 25% of new drug can­di­dates from its pipeline. The …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

Pfiz­er CEO says op­por­tu­ni­ties with Trump ‘clear­ly out­weigh’ the risks for phar­ma

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times